George G Nomikos
Keine laufenden Positionen mehr
Profil
George G Nomikos worked as a Scientific Director-Scientific Affairs at Amgen, Inc. from 2006 to 2007.
He also served as a Director-Scientific Affairs at Cynapsus Therapeutics, Inc. He was a Research Scientist-Neuroscience Discovery at Eli Lilly & Co. from 1998 to 2006.
Additionally, he worked as an Associate Professor at Karolinska Institutet.
Currently, he is the SVP-Medical & Clinical Science at Scholar Rock Holding Corp.
from 2019 to 2022.
He will be serving as the Chief Medical Officer at Lipocine, Inc. starting from 2022 to 2023.
Dr. Nomikos holds a doctorate degree from the University of British Columbia and the National & Kapodistrian University of Athens, which he received in 1987.
Ehemalige bekannte Positionen von George G Nomikos
| Unternehmen | Position | Ende |
|---|---|---|
| LIPOCINE INC. | Chief Tech/Sci/R&D Officer | 01.04.2023 |
| SCHOLAR ROCK HOLDING CORPORATION | Chief Tech/Sci/R&D Officer | 02.11.2022 |
| AMGEN INC. | Corporate Officer/Principal | 01.10.2007 |
| ELI LILLY AND COMPANY | Corporate Officer/Principal | 01.01.2006 |
| Karolinska Institutet | Corporate Officer/Principal | - |
Ausbildung von George G Nomikos
| University of British Columbia | Doctorate Degree |
| National & Kapodistrian University of Athens | Doctorate Degree |
Erfahrungen
Besetzte Positionen
Aktive
Inaktive
Börsennotierte Unternehmen
Private Unternehmen
Beziehungen
Beziehungen ersten Grades
Unternehmen ersten Grades
Herr
Frau
Aufsichtsräte
Führungskräfte
Unternehmensverbindungen
| Börsennotierte Unternehmen | 4 |
|---|---|
| AMGEN INC. | Health Technology |
| ELI LILLY AND COMPANY | Health Technology |
| LIPOCINE INC. | Health Technology |
| SCHOLAR ROCK HOLDING CORPORATION | Health Technology |
| Private Unternehmen | 1 |
|---|---|
Cynapsus Therapeutics, Inc.
 Cynapsus Therapeutics, Inc. Pharmaceuticals: MajorHealth Technology Cynapsus Therapeutics, Inc. operated as a pharmaceutical company, which developed an improved dosing formulation of an approved drug used to treat the symptoms of Parkinson's disease. The company was founded by Andrew Williams and David Hill on January 16, 2004 and was headquartered in Toronto, Canada. | Health Technology |
